Halozyme Therapeutics IncHALO
Price$106.94Intrinsic value$154.9245% above price

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $1.7B+63.9% YoYTTM through 30 Jun 2026
Net Income $413.6M-6.9% YoYTTM through 30 Jun 2026
Free Cash Flow $806.2MTTM through 30 Jun 2026

Margins

Current
Gross Margin79.0%
EBITDA Margin36.8%
Operating Margin49.0%
Net Margin24.9%

Returns

223.3%ROE
18.3%ROA
19.4%ROIC

Balance Sheet Health

Debt / Equity9.76x
Current Ratio2.76x
Net Debt$1.8B
Cash & Equivalents$163.1M

Quality Metrics

Altman Z-Score4.99
Piotroski F-Score5 / 9
FCF Margin48.5%
Rule of 4059.9
Earnings-Beat Rate75.0%

Multi-Year Trend

Revenue
'19'20'21'22'23'24'25
FY2025: $1.4B
Diluted EPS$3.41TTM
'19'20'21'22'23'24'25
FY2025: $2.56

Dividend

No dividend

Capital Allocation

Capex Intensity0.7%
All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.